StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Performance
Shares of LPCN opened at $5.01 on Friday. Lipocine has a 1 year low of $2.31 and a 1 year high of $7.15. The stock has a market capitalization of $26.80 million, a PE ratio of -1.64 and a beta of 1.11. The stock has a 50-day simple moving average of $4.69 and a 200-day simple moving average of $3.67.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. Analysts predict that Lipocine will post -1.49 EPS for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Garmin Navigates to New Highs Driven By Wearables Trend
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Energy and Oil Stocks Explained
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
